As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

Delinia

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Rectify

Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.

ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.

Triplet Therapeutics

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

HotSpot Therapeutics

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Akero Therapeutics

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Vedere Bio II

Next generation ocular gene
therapies for vision restoration
and vision preservation

Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Ikena Oncology

Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)

Infacare

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Gemini Therapeutics

Precision therapeutics for
genetically-defined dry AMD
(NASDAQ: GMTX) Jan 2021

Aerovate Therapeutics

Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)

ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Harbour Antibodies

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Day One Biopharmaceuticals

Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)

Vigil Neuroscience

Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)

deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Rodin Therapeutics

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Kymera Therapeutics

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

AVROBIO

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Magenta Therapeutics

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Translate Bio

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Synlogic

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

K36 Therapeutics

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics

F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

Korro Bio

Leading the
next frontier in
RNA therapeutics

Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Kinaset Therapeutics

Novel therapeutics
for severe
respiratory diseases

Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Replimune

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Cogent Biosciences

Precision therapeutics
for genetically defined
diseases

Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Affinia Therapeutics

Building
the future of
gene therapy

Scorpion Therapeutics

Broadening the reach and
impact of precision medicine
to more people with cancer

Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Disarm Therapeutics

Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020

Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Arkuda Therapeutics

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Larimar Therapeutics

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Bicycle Therapeutics

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Dyne Therapeutics

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Accent Therapeutics

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Surface Oncology

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Cadent Therapeutics

Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020

Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Xilio Therapeutics

Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)

Curie Therapeutics

Curie Therapeutics is discovering and developing safe, effective, and highly targeted radiopharmaceuticals.

Generation Bio

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Chroma Medicine

Harnessing the power of the epigenome to develop precision genomic therapeutics.

Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Versanis Bio

Developing first-in-class
medicines for medical conditions
prevalent in older adults

Q32 Bio

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Spero Therapeutics

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Remix Therapeutics

Reprogramming RNA processing
to address underlying
drivers of disease

Obsidian Therapeutics

New class of
regulated cell and
gene therapies

Disc Medicine

Applying new insights in
hepcidin biology to
treat hematologic diseases

Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases

Be Biopharma

Engineered
B cells
as medicines

Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007